Updates in the management of brain metastases

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 18; no. 8; pp. 1043 - 1065
• Main Authors: Arvold, Nils D., Lee, Eudocia Q., Mehta, Minesh P., Margolin, Kim, Alexander, Brian M., Lin, Nancy U., Anders, Carey K., Soffietti, Riccardo, Camidge, D. Ross, Vogelbaum, Michael A., Dunn, Ian F., Wen, Patrick Y.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.08.2016
• Series: Editor's choice
• Subjects: Adult; Brain Neoplasms - pathology; Brain Neoplasms - secondary; Brain Neoplasms - therapy; Clinical Trials as Topic; Cognition - radiation effects; Cranial Irradiation - adverse effects; Cranial Irradiation - methods; Drug Therapy - methods; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Invited Reviews; Male; Radiotherapy - adverse effects; Treatment Outcome; chemotherapy; brain metastases; stereotactic radiosurgery; surgery; whole brain radiation
• ISSN: 1522-8517; 1523-5866; 1523-5866
• DOI: 10.1093/neuonc/now127

The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survival, associated with increased time at risk for developing BM. Development of systemic therapies capable of preventing BM and controlling both intracranial and extracranial disease once BM are diagnosed is paramount. The increase in use of stereotactic radiosurgery alone for many patients with multiple BM is an outgrowth of the desire to employ treatments focused on local control while minimizing cognitive effects associated with whole brain radiotherapy. Complications from BM and their treatment must be considered in comprehensive patient management, especially with greater awareness that the majority of patients do not die from their BM. Being aware of significant heterogeneity in prognosis and therapeutic options for patients with BM is crucial for appropriate management, with greater attention to developing individual patient treatment plans based on predicted outcomes; in this context, recent prognostic models of survival have been extensively revised to incorporate molecular markers unique to different primary cancers.